Effectiveness of Tocilizumab for Graves Orbitopathy
Author Information
Author(s): Wang Mingyang, Qin Bixuan, Liu Cuihong, Liu Honglei, Li Dongmei
Primary Institution: Beijing Tongren Hospital, Capital Medical University
Hypothesis
The study aims to evaluate the effectiveness of tocilizumab in treating Graves orbitopathy that is resistant to conventional therapy.
Conclusion
Tocilizumab is a valuable treatment option for patients with active, corticosteroid-resistant Graves orbitopathy.
Supporting Evidence
- Significant improvements were found in visual acuity, intraocular pressure, proptosis, clinical activity score, and TRAb levels.
- 71.4% of adults and 60% of pediatric patients experienced a decrease in clinical activity score by at least 2 points.
- 89.3% of adults and 60% of pediatric patients achieved low activity disease status after treatment.
Takeaway
This study shows that a medicine called tocilizumab can help people with a serious eye problem caused by thyroid disease, especially when other treatments don't work.
Methodology
This observational study included 79 patients with Graves orbitopathy, treated with tocilizumab every 28 days for 4 months, assessing various ocular parameters and clinical activity scores.
Potential Biases
The study design may have inherent biases due to its observational nature and the lack of a control group.
Limitations
The study had a small number of pediatric patients and could not determine recurrence rates after discontinuation of tocilizumab.
Participant Demographics
79 Chinese patients, including 15 pediatric patients, with a mean age of 39.87 years; 65.8% were female.
Statistical Information
P-Value
p<0.05
Confidence Interval
0.003∼0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website